JP2010520268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520268A5 JP2010520268A5 JP2009552266A JP2009552266A JP2010520268A5 JP 2010520268 A5 JP2010520268 A5 JP 2010520268A5 JP 2009552266 A JP2009552266 A JP 2009552266A JP 2009552266 A JP2009552266 A JP 2009552266A JP 2010520268 A5 JP2010520268 A5 JP 2010520268A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- optionally substituted
- represent
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 64
- 125000001424 substituent group Chemical group 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000005843 halogen group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 239000002671 adjuvant Substances 0.000 claims 7
- 238000006243 chemical reaction Methods 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000023504 respiratory system disease Diseases 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 239000013066 combination product Substances 0.000 claims 4
- 229940127555 combination product Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- -1 -R 3a Chemical group 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 238000006722 reduction reaction Methods 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 208000028185 Angioedema Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 201000002772 Kwashiorkor Diseases 0.000 claims 1
- 208000004221 Multiple Trauma Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000037656 Respiratory Sounds Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010051222 Toxic oil syndrome Diseases 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047924 Wheezing Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 210000003372 endocrine gland Anatomy 0.000 claims 1
- 208000019097 eosinophilic gastrointestinal disease Diseases 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000004792 oxidative damage Effects 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 238000005809 transesterification reaction Methods 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90478307P | 2007-03-05 | 2007-03-05 | |
| US90478407P | 2007-03-05 | 2007-03-05 | |
| PCT/GB2008/000724 WO2008107661A1 (en) | 2007-03-05 | 2008-03-04 | New methylenebisphenyl compounds useful in the treatment of inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520268A JP2010520268A (ja) | 2010-06-10 |
| JP2010520268A5 true JP2010520268A5 (enExample) | 2011-04-28 |
Family
ID=39415403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552266A Pending JP2010520268A (ja) | 2007-03-05 | 2008-03-04 | 炎症の治療に有用な新しいメチレンビスフェニル化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100144872A1 (enExample) |
| EP (1) | EP2132169A1 (enExample) |
| JP (1) | JP2010520268A (enExample) |
| CA (1) | CA2680139A1 (enExample) |
| WO (1) | WO2008107661A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010029300A1 (en) * | 2008-09-12 | 2010-03-18 | Biolipox Ab | Bis aromatic compounds for use in the treatment of inflammation |
| CA3041868C (en) * | 2008-10-09 | 2023-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase |
| US20120035217A1 (en) | 2009-03-12 | 2012-02-09 | Biolipox Ab | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
| JP2012520276A (ja) | 2009-03-12 | 2012-09-06 | バイオリポックス エービー | Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物 |
| US20110319431A1 (en) | 2009-03-12 | 2011-12-29 | Biolipox Ab | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
| JP2012520275A (ja) | 2009-03-12 | 2012-09-06 | バイオリポックス エービー | Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物 |
| EP2332529A1 (de) * | 2009-12-14 | 2011-06-15 | Grünenthal GmbH | Substituierte aromatische Diamine als Liganden der vesikulären Glutamat-Transporter 1 und 2 (vGLUT1 und vGLUT2) |
| EP2545036A1 (en) | 2010-03-12 | 2013-01-16 | Biolipox AB | Bis aromatic compounds for use as ltc4 synthase inhibitors |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| DK2915804T3 (da) | 2012-10-31 | 2019-06-03 | Fujifilm Toyama Chemical Co Ltd | Nyt aminderivat eller salt deraf som TNF-alpha-inhibitorer |
| WO2019235572A1 (ja) * | 2018-06-06 | 2019-12-12 | 富士フイルム株式会社 | 固形がんの処置剤および医薬組成物 |
| EP3804722A4 (en) * | 2018-06-06 | 2022-04-13 | National University Corporation Hokkaido University | TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION AGAINST GLIOMA |
| WO2019235571A1 (ja) * | 2018-06-06 | 2019-12-12 | 富士フイルム株式会社 | 血液がんの処置剤および医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB557549A (en) * | 1942-04-23 | 1943-11-25 | John David Kendall | Improvements in or relating to dyestuffs |
| GB577387A (en) * | 1943-04-16 | 1946-05-16 | Du Pont | Improvements in or relating to dyestuff intermediates and their use in colour photography |
| IE913866A1 (en) * | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
| US7264932B2 (en) | 1999-09-24 | 2007-09-04 | Applera Corporation | Nuclease inhibitor cocktail |
| CN1652759A (zh) * | 2002-03-11 | 2005-08-10 | 泰博特克药品有限公司 | 小分子进入抑制剂 |
| US20070032418A1 (en) * | 2003-02-25 | 2007-02-08 | Ambion, Inc | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same |
| ATE545413T1 (de) * | 2004-03-15 | 2012-03-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| JPWO2006077671A1 (ja) * | 2005-01-19 | 2008-06-19 | 株式会社ディーアンドエムホールディングス | プロジェクタ装置 |
| JP4709827B2 (ja) | 2005-02-28 | 2011-06-29 | 東芝ストレージデバイス株式会社 | 記憶装置のトラックピッチ検査方法、プログラム及び記憶装置 |
| EP2005177B1 (en) | 2006-04-06 | 2013-07-10 | Janssen R&D Ireland | A homogeneous time resolved fluorescence based test method |
-
2008
- 2008-03-04 EP EP08709584A patent/EP2132169A1/en not_active Withdrawn
- 2008-03-04 CA CA002680139A patent/CA2680139A1/en not_active Abandoned
- 2008-03-04 US US12/529,913 patent/US20100144872A1/en not_active Abandoned
- 2008-03-04 WO PCT/GB2008/000724 patent/WO2008107661A1/en not_active Ceased
- 2008-03-04 JP JP2009552266A patent/JP2010520268A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520268A5 (enExample) | ||
| JP7145931B2 (ja) | 化合物の結晶多形、その製造方法及び用途 | |
| ES2605388T3 (es) | Compuesto inhibidor de Trk | |
| JP2010538052A5 (enExample) | ||
| IL126558A (en) | Benzofuran carboxamides and pharmaceutical compositions containing them | |
| KR20100067102A (ko) | 염증의 치료에 유용한 비스-방향족 화합물 | |
| JP2006520373A5 (enExample) | ||
| CN105120866A (zh) | 与毒性醛相关的疾病和治疗 | |
| HRP20141209T2 (hr) | Modulatori receptora prostaciklina (pgi2) korisni za liječenje poremećaja povezanih s time | |
| JP2011520854A (ja) | 薬剤としての使用のためのビスアリール化合物 | |
| JP2010501587A5 (enExample) | ||
| JP2013518110A5 (enExample) | ||
| US7378437B2 (en) | Drugs for diabetes | |
| JP2017528496A5 (enExample) | ||
| JP2010520268A (ja) | 炎症の治療に有用な新しいメチレンビスフェニル化合物 | |
| CN102453024A (zh) | 一种尼罗替尼盐酸盐晶形及其制备方法 | |
| RU2007101703A (ru) | Индолы, полезные при лечении воспаления | |
| TW201702228A (zh) | 新穎化合物及用途 | |
| JP2008524249A5 (enExample) | ||
| JP2009511559A5 (enExample) | ||
| CN106631865A (zh) | 一种燕麦生物碱及其衍生物的制备方法 | |
| WO2001042244A1 (en) | Novel 1,8-naphthyridin-2(1h)-one derivatives | |
| CN103664606B (zh) | 一种氟比洛芬酯类化合物的制备方法 | |
| SK50052004A3 (sk) | Nová forma N-(trans-4-izopropylcyklohexylkarbonyl)-D-fenylalanínu | |
| ES2204171T3 (es) | Derivados de furopiridina y su utilizacion terapeutica. |